Related references
Note: Only part of the references are listed.Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma
Lingzhi Yan et al.
CANCER MEDICINE (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Sham Mailankody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Jesus G. Berdeja et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Eugenia Zah et al.
NATURE COMMUNICATIONS (2020)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos et al.
LANCET (2020)
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
Paola Tacchetti et al.
Lancet Haematology (2020)
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes
Melissa Alsina et al.
BLOOD (2020)
A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ajai Chari et al.
BLOOD (2020)
Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies
Caitlin L. Costello et al.
BLOOD (2020)
Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Meletios A. Dimopoulos et al.
BLOOD (2020)
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Alfred L. Garfall et al.
BLOOD (2020)
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Deepu Madduri et al.
BLOOD (2020)
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2020)
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma
Carlos Fernandez de Larrea et al.
BLOOD CANCER DISCOVERY (2020)
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim Farooq et al.
OPHTHALMOLOGY AND THERAPY (2020)
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
Yu-Tzu Tai et al.
LEUKEMIA (2019)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel et al.
BLOOD CANCER JOURNAL (2019)
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Philippe Moreau et al.
BLOOD CANCER JOURNAL (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson et al.
LANCET ONCOLOGY (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Dennis Cooper et al.
BLOOD (2019)
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Noopur S. Raje et al.
BLOOD (2019)
Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
Andrew J. Cowan et al.
BLOOD (2019)
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Luciano J. Costa et al.
BLOOD (2019)
AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
Shih-Feng Cho et al.
BLOOD (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts et al.
BLOOD ADVANCES (2019)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Sara Bringhen et al.
LEUKEMIA (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel et al.
LANCET ONCOLOGY (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial
Pieter Sonneveld et al.
BLOOD (2018)
Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies
Michele Cavo et al.
BLOOD (2018)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Current status of chimeric antigen receptor therapy for haematological malignancies
Shannon Maude et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai et al.
BLOOD (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Improved long-term survival in multiple myeloma up to the age of 80 years
S. Y. Kristinsson et al.
LEUKEMIA (2014)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2011)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL
Micah J. Benson et al.
JOURNAL OF IMMUNOLOGY (2008)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
JA Gross et al.
NATURE (2000)
Share Paper
